CALC vs. AEON, ANVS, IMMX, CKPT, RPHM, CELU, KZR, EGRX, ALRN, and ELDN
Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include AEON Biopharma (AEON), Annovis Bio (ANVS), Immix Biopharma (IMMX), Checkpoint Therapeutics (CKPT), Reneo Pharmaceuticals (RPHM), Celularity (CELU), Kezar Life Sciences (KZR), Eagle Pharmaceuticals (EGRX), Aileron Therapeutics (ALRN), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical preparations" industry.
CalciMedica (NASDAQ:CALC) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
AEON Biopharma's return on equity of 0.00% beat CalciMedica's return on equity.
CalciMedica received 5 more outperform votes than AEON Biopharma when rated by MarketBeat users.
CalciMedica has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
In the previous week, CalciMedica had 4 more articles in the media than AEON Biopharma. MarketBeat recorded 10 mentions for CalciMedica and 6 mentions for AEON Biopharma. CalciMedica's average media sentiment score of 0.78 beat AEON Biopharma's score of 0.06 indicating that CalciMedica is being referred to more favorably in the media.
22.8% of AEON Biopharma shares are held by institutional investors. 53.3% of CalciMedica shares are held by insiders. Comparatively, 20.0% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
CalciMedica presently has a consensus target price of $18.67, indicating a potential upside of 240.63%. AEON Biopharma has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given AEON Biopharma's higher possible upside, analysts plainly believe AEON Biopharma is more favorable than CalciMedica.
Summary
CalciMedica beats AEON Biopharma on 7 of the 11 factors compared between the two stocks.
Get CalciMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CalciMedica Competitors List
Related Companies and Tools
